Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR444200
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SAR444200 is a novel bispecific NANOBODY T cell engager developed by Sanofi. It simultaneously binds to the T-cell receptor alpha/beta (TCRαβ) on cytotoxic T cells and glypican-3 (GPC3) on tumor cells, thereby co-engaging T cells with GPC3-expressing tumor cells. This dual binding results in targeted T cell-dependent cellular cytotoxicity against GPC3-positive solid tumors. The drug is being evaluated as an intravenous therapy in adult patients with advanced or metastatic solid tumors expressing GPC3, including hepatocellular carcinoma and other malignancies. Clinical trials have shown that it is generally tolerable at tested doses and has demonstrated early signs of antitumor activity[1][2][4][5][6].
- Other names
- anti-GPC3/TCR nanobody SAR444200
02
Targets
GPC3 (Glypican-3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on SAR444200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR444200.